A cisplatin‑incorporated liposome that targets the epidermal growth factor receptor enhances radiotherapeutic efficacy without nephrotoxicity

Jung,Joohee; Jeong,Seong‑Yun; Park,Seok Soon; Shin,Seol Hwa; Ju,Eun Jin; Choi,Jinhyang; Park,Jaesook; Lee,Jae Hee; Kim,Inki; Suh,Young‑Ah; Hwang,Jung Jin; Kuroda,Shun'ichi; Lee,Jung Shin; Song,Si Yeol; Choi,Eun Kyung

doi:10.3892/ijo.2014.2806

A cisplatin‑incorporated liposome that targets the epidermal growth factor receptor enhances radiotherapeutic efficacy without nephrotoxicity

Authors:
- Joohee Jung
- Seong‑Yun Jeong
- Seok Soon Park
- Seol Hwa Shin
- Eun Jin Ju
- Jinhyang Choi
- Jaesook Park
- Jae Hee Lee
- Inki Kim
- Young‑Ah Suh
- Jung Jin Hwang
- Shun'ichi Kuroda
- Jung Shin Lee
- Si Yeol Song
- Eun Kyung Choi
View Affiliations

Affiliations: Institute for Innovative Cancer Research, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138‑736, Republic of Korea, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138‑736, Republic of Korea, Department of Bioengineering Sciences, Graduate School of Bioagricultural Sciences Nagoya University, Aichi 464‑8601, Japan
Published online on: December 22, 2014 https://doi.org/10.3892/ijo.2014.2806
Pages: 1268-1274

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radiotherapy (RT) is one of the major modalities for non‑small cell lung cancer (NSCLC), but its efficacy is often compromised by cellular resistance caused by various mechanisms including the overexpression of epidermal growth factor receptor (EGFR). Although cis‑diamminedichloroplatinum(Ⅱ) (cisplatin, CDDP) has been well characterized as an effective radiosensitizer, its clinical application is limited by its severe nephrotoxic effects. In our current study, we developed a CDDP‑incorporated liposome (LP) conjugated with EGFR antibodies (EGFR:LP‑CDDP) and evaluated its potential to radiosensitize EGFR‑overexpressing cells without exerting nephrotoxic effects. EGFR:LP‑CDDP showed higher cytotoxicity than non‑targeting liposomal CDDP (LP‑CDDP) in the cells expressing EGFR in vitro. In an A549 cell‑derived xenograft tumor mouse model, increased delays in tumor growth were observed in the mice treated with a combination of EGFR:LP‑CDDP and radiation. Notably, the EGFR:LP‑CDDP‑treated animals showed no differences in body weight loss, survival rates of nephrotoxicity compared with untreated control mice. In contrast, the use of CDDP caused lower body weights and poorer survival outcomes accompanied by a significant level of nephrotoxicity [e.g., decreased kidney weight, increased blood urea nitrogen (BUN) and creatinine, and pathological change]. These findings suggest the feasibility of using EGFR:LP‑CDDP to radiosensitize cells in a targeted manner without inducing nephrotoxic effects. This compound may therefore have clinical potential as part of a tailored chemoradiotherapy strategy.

View Figures

View References

1	Ghafoori P, Marks LB, Vujaskovic Z and Kelsey CR: Radiation-induced lung injury. Assessment, management, and prevention. Oncology (Williston Park). 22:37–47; discussion 52–33. 2008.
2	Graves EE, Maity A and Le QT: The tumor microenvironment in non-small-cell lung cancer. Semin Radiat Oncol. 20:156–163. 2010. View Article : Google Scholar : PubMed/NCBI
3	Baas P, Belderbos JS and van den Heuvel M: Chemoradiation therapy in nonsmall cell lung cancer. Curr Opin Oncol. 23:140–149. 2011. View Article : Google Scholar
4	Giaccone G: Twenty-five years of treating advanced NSCLC: what have we achieved? Ann Oncol. 4(Suppl 15): iv81–iv83. 2004.
5	Yao X, Panichpisal K, Kurtzman N and Nugent K: Cisplatin nephrotoxicity: a review. Am J Med Sci. 334:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
6	Wainford RD, Weaver RJ, Stewart KN, Brown P and Hawksworth GM: Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology. 249:184–193. 2008. View Article : Google Scholar : PubMed/NCBI
7	Wang M and Thanou M: Targeting nanoparticles to cancer. Pharmacol Res. 62:90–99. 2010. View Article : Google Scholar : PubMed/NCBI
8	Hwang KJ, Padki MM, Chow DD, Essien HE, Lai JY and Beaumier PL: Uptake of small liposomes by non-reticuloendothelial tissues. Biochim Biophys Acta. 901:88–96. 1987. View Article : Google Scholar : PubMed/NCBI
9	Drummond DC, Meyer O, Hong K, Kirpotin DB and Papahadjopoulos D: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 51:691–743. 1999.PubMed/NCBI
10	Jeong SY, Park SJ, Yoon SM, et al: Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization. J Control Release. 139:239–245. 2009. View Article : Google Scholar : PubMed/NCBI
11	van der Meel R, Oliveira S, Altintas I, et al: Tumor-targeted nanobullets: anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. J Control Release. 159:281–289. 2012. View Article : Google Scholar : PubMed/NCBI
12	Song S, Liu D, Peng J, et al: Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm. 363:155–161. 2008. View Article : Google Scholar : PubMed/NCBI
13	Liang K, Ang KK, Milas L, Hunter N and Fan Z: The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys. 57:246–254. 2003. View Article : Google Scholar : PubMed/NCBI
14	Baumann M, Krause M, Dikomey E, et al: EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol. 83:238–248. 2007. View Article : Google Scholar : PubMed/NCBI
15	Ansell SM, Harasym TO, Tardi PG, Buchkowsky SS, Bally MB and Cullis PR: Antibody conjugation methods for active targeting of liposomes. Methods Mol Med. 25:51–68. 2000.PubMed/NCBI
16	Kolhatkar R, Lote A and Khambati H: Active tumor targeting of nanomaterials using folic acid, transferrin and integrin receptors. Curr Drug Discov Technol. 8:197–206. 2011. View Article : Google Scholar : PubMed/NCBI
17	Hirai M, Minematsu H, Hiramatsu Y, et al: Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. Int J Pharm. 391:274–283. 2010. View Article : Google Scholar : PubMed/NCBI
18	Hirai M, Minematsu H, Kondo N, Oie K, Igarashi K and Yamazaki N: Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. Biochem Biophys Res Commun. 353:553–558. 2007. View Article : Google Scholar
19	Jung J, Kim EJ, Chung HK, Park HJ, Jeong SY and Choi EK: c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer. Int J Oncol. 40:385–390. 2012.
20	Tseng CL, Su WY, Yen KC, Yang KC and Lin FH: The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials. 30:3476–3485. 2009. View Article : Google Scholar : PubMed/NCBI
21	Nishiyama N, Okazaki S, Cabral H, et al: Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 63:8977–8983. 2003.PubMed/NCBI
22	Ajima K, Murakami T, Mizoguchi Y, et al: Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns. ACS Nano. 2:2057–2064. 2008. View Article : Google Scholar
23	Castelo-Branco PA, Rubinger MM, de Alves LC, et al: Synthesis and antifungal activity of aromatic bis-gamma-lactones analogous to avenaciolide. Chem Biodivers. 4:2745–2754. 2007. View Article : Google Scholar : PubMed/NCBI
24	Yaklin KM: Acute kidney injury: an overview of pathophysiology and treatments. Nephrol Nurs J. 38:13–19. 2011.PubMed/NCBI
25	Dirkes S: Acute kidney injury: not just acute renal failure anymore? Crit Care Nurse. 31:37–50. 2011. View Article : Google Scholar : PubMed/NCBI